Human colon cancer profiles show differential microRNA expression depending on mismatch repair status and are characteristic of undifferentiated proliferative states by Sarver, Aaron L et al.
BioMed  Central
Open Access
Page 1 of 15
(page number not for citation purposes)
BMC Cancer
Research article
Human colon cancer profiles show differential microRNA 
expression depending on mismatch repair status and are 
characteristic of undifferentiated proliferative states
Aaron L Sarver*1, Amy J French2, Pedro M Borralho3, 
Venugopal Thayanithy4, Ann L Oberg5, Kevin AT Silverstein1, 
Bruce W Morlan5, Shaun M Riska5, Lisa A Boardman6, Julie M Cunningham2, 
Subbaya Subramanian4, Liang Wang2,  T o mCS m y r k 2, Cecilia MP Rodrigues3, 
Stephen N Thibodeau2 and Clifford J Steer7,8
Address: 1Biostatistics and Informatics, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, USA, 2Department of 
Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA, 3Research Institute for Medicines and Pharmaceutical Sciences, 
Faculty of Pharmacy, University of Lisbon, Lisbon, Portugal, 4Department of Laboratory Medicine and Pathology, University of Minnesota, 
Minneapolis, Minnesota, USA, 5Department of Health Sciences Research, Division of Biomedical Informatics and Statistics, Mayo Clinic, 
Rochester, Minnesota, USA, 6Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA, 7Department of Medicine, 
University of Minnesota, Minneapolis, Minnesota, USA and 8Genetics, Cell Biology and Development, University of Minnesota, Minneapolis, 
Minnesota, USA
Email: Aaron L Sarver* - sarver@umn.edu; Amy J French - french.amy@mayo.edu; Pedro M Borralho - borralho@ff.ul.pt; 
Venugopal Thayanithy - thaya003@umn.edu; Ann L Oberg - Oberg.Ann@mayo.edu; Kevin AT Silverstein - silve023@umn.edu; 
Bruce W Morlan - Morlan.Bruce@mayo.edu; Shaun M Riska - Riska.Shaun@mayo.edu; Lisa A Boardman - boardman.lisa@mayo.edu; 
Julie M Cunningham - cunningham.julie@mayo.edu; Subbaya Subramanian - subree@umn.edu; Liang Wang - Wang.Liang@mayo.edu; 
Tom C Smyrk - Smyrk.Thomas@mayo.edu; Cecilia MP Rodrigues - cmprodrigues@ff.ul.pt; Stephen N Thibodeau - sthibodeau@mayo.edu; 
Clifford J Steer - steer001@umn.edu
* Corresponding author    
Abstract
Background: Colon cancer arises from the accumulation of multiple genetic and epigenetic
alterations to normal colonic tissue. microRNAs (miRNAs) are small, non-coding regulatory RNAs
that post-transcriptionally regulate gene expression. Differential miRNA expression in cancer
versus normal tissue is a common event and may be pivotal for tumor onset and progression.
Methods: To identify miRNAs that are differentially expressed in tumors and tumor subtypes, we
carried out highly sensitive expression profiling of 735 miRNAs on samples obtained from a
statistically powerful set of tumors (n = 80) and normal colon tissue (n = 28) and validated a subset
of this data by qRT-PCR.
Results: Tumor specimens showed highly significant and large fold change differential expression
of the levels of 39 miRNAs including miR-135b, miR-96, miR-182, miR-183, miR-1, and miR-133a,
relative to normal colon tissue. Significant differences were also seen in 6 miRNAs including miR-
31 and miR-592, in the direct comparison of tumors that were deficient or proficient for mismatch
repair. Examination of the genomic regions containing differentially expressed miRNAs revealed
that they were also differentially methylated in colon cancer at a far greater rate than would be
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expected by chance. A network of interactions between these miRNAs and genes associated with
colon cancer provided evidence for the role of these miRNAs as oncogenes by attenuation of
tumor suppressor genes.
Conclusion: Colon tumors show differential expression of miRNAs depending on mismatch
repair status. miRNA expression in colon tumors has an epigenetic component and altered
expression that may reflect a reversion to regulatory programs characteristic of undifferentiated
proliferative developmental states.
Background
Colon cancer (CC) is the second most frequent cause of
cancer-related death in the United States and in Europe
[1,2]. The development of CC is considered a stepwise
process with the accumulation of different genetic and
epigenetic alterations. Most tumors (~85%) are generated
by chromosomal instability (CIN) and associated with
high frequency aneuploidy and allelic imbalance. The
remaining 15% have defective DNA mismatch repair
(dMMR), which is frequently measured by either the pres-
ence of microsatellite instability (MSI) or by testing for
loss of the protein products for genes involved in DNA
mismatch repair, most commonly MLHI, MSH2, MSH6,
and PMS2 [3]. Sporadic CCs with dMMR have distinctive
clinical and pathological features that include proximal
colon predominance, poor differentiation and/or muci-
nous histology, intra- and peritumoral lymphocytic infil-
tration, diploid DNA content [3] and generally have a
better prognosis [4]. The presence of MSI-H tumor pheno-
type and loss of protein expression of MLHl and MSH2 is
highly concordant [5].
Recent progress has been made in CC screening [6] and
treatment protocols [7]. Currently, the most important
prognostic factor for patients is pathologic tumor staging
based on the tumor-node-metastasis (TNM) system [8].
However, several pathologic and clinical features have
been associated with increased risk of tumor recurrence in
resectable CC [7]. Between 20 and 25% of stage II CC
patients develop recurrence and die from the disease [9].
Therefore, it is imperative to identify and develop accu-
rate, reliable and sensitive biomarkers.
Genome-wide approaches have reshaped the landscape of
cancer research. Meta-analysis of multi-study data has
allowed the identification of overlapping sets of differen-
tially expressed genes that may have biomarker potential
[10]. Emphasis on genome-wide gene expression analyses
has been driven by the general view that alterations in
protein-coding oncogenes or tumor-suppressor genes
underlie tumorigenesis. However, the discovery of a grow-
ing class of small non-coding RNAs, termed miRNAs, has
opened a new field of cancer research and revealed the
complexity of cancer biology. miRNAs regulate gene
expression post-transcriptionally by translational attenua-
tion/repression or cleavage of target mRNAs [11], thereby
adding a new dimension to the regulation of gene expres-
sion [12]. Further, aberrant expression of miRNAs has
been associated with a growing list of cancers [13].
The potential use of miRNAs in diagnosis and prognosis
has been demonstrated for several forms of cancer
[14,15]. miRNA expression profiles may be better-suited
targets for the discovery of novel cancer biomarkers com-
pared to gene expression profiles. This is supported by a
report demonstrating the ability of miRNA profiles to cor-
rectly classify human cancers of unknown primary origin
as well as poorly differentiated tumors [16]. A growing
number of studies have addressed miRNA expression in
CC [17-20]. However, comparison across studies is lim-
ited by differences in profiling platform, quantity of
miRNA obtainable, methodology, in some cases sample
number and a paucity of clinicopathologic data. Conse-
quently, translation of results into clinically useful and
widely applicable biomarkers is hampered. Importantly, a
potentially strong contributor to the variability of data
among different studies relates to the tumor resection pro-
cedures. The inadvertent collection of surrounding resid-
ual non-tumor tissue may skew experimental results,
diluting quantitative estimates of particular miRNA spe-
cies based on the extent and type of tissue present in the
sample. Most studies do not specifically address this
potential problem.
In this study, global miRNA expression was evaluated in
80 colon tumors and 28 normal mucosa samples using
the BeadArray™ platform (Illumina, Inc.) to evaluate glo-
bal miRNA expression of 735 miRNA targets [21]. Our
results demonstrate that, in a sufficiently statistically pow-
ered number of tumors, a larger set of miRNAs than has
previously been reported is differentially expressed
between normal colon and tumor tissue. Additionally,
specific miRNAs are significantly differentially expressed
between tumors of deficient and proficient mismatch
repair status (dMMR and pMMR, respectively).
Methods
Colon Cancer Samples
CC biospecimens were obtained from Mayo Clinic
Rochester patients with colorectal neoplasia beginning inBMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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1995. Of the consented patients, US residents who had
only CC were included in this study. The majority of
patients in the registry are from the surrounding five-state
region. Pathologic tumor staging was carried out using the
tumor-node-metastasis (TNM) system[8]. Collection of
tissue material and review of patient records to obtain
clinical information were performed under IRB-approved
protocol.
Mismatch Repair Status
Defective DNA mismatch repair (dMMR) was defined by
the presence of microsatellite instability (MSI-H) and/or
the absence of protein expression for hMLH1. Proficient
DNA mismatch repair (pMMR) was defined by the
absence of microsatellite instability (MSS/MSI-L) and the
presence of normal protein expression for hMLH1. MSI in
CC cases was compared with paired normal and tumor
DNA isolated (Qiagen DNA extraction kit) from formalin-
fixed, paraffin-embedded (FFPE) material. Tumors were
classified as MSI-H if > 30% of markers demonstrated
instability and as MSS/MSI-L if < 30% demonstrated MSI
[22,23]. Immunohistochemical analysis of hMLH1
expression was performed on FFPE samples, as previously
described [5].
RNA Extraction
Following harvest, tissue samples were immediately snap
frozen and stored at -80°C. For each case, frozen tumor
tissue was cut on a cryostat to generate a hematoxylin and
eosin (H&E) stained slide. Tumors were then evaluated
for content of tumor present, areas of tumor containing at
last 70% tumor or greater were macro-dissected and tissue
equivalent to 7 mm2 and 10-microns thick was then sec-
tioned and placed in a vial containing 400 uL of RLT
buffer (QIAGEN, Chatsworth, CA) including 4 μL of β-
mercaptoethanol. The vial was then stored at -80°C until
utilized for RNA extraction using TRIzol® LSTrizol© (Invit-
rogen, Corp., Carlsbad, CA), according to the manufac-
turer's instructions.
miRNA Expression by qRT-PCR
qRT-PCR was carried using normalization to U6 snRNA.
First strand cDNA was synthesized from 1 μg of total RNA
using a miScript reverse transcription kit (Qiagen, Valen-
cia, CA). miRNA was quantified with an miRscript SYBR
Green PCR kit (Catl: 218073, Qiagen, Valencia, CA) using
cDNA equivalent of 50 ng total RNA per reaction. Mature
miRNA-specific forward primers [see Additional file 1]
were purchased from a vendor (IDT, USA) and the univer-
sal reverse primer provided by the manufacturer. Real-
time PCR was performed at 55°C annealing following
standard protocol of the manufacturer in 7500 Real Time
PCR system (Applied Biosystem, USA) and threshold
cycles (CT) were calculated using Sequence Detection Soft-
ware (SDS v1.2.1, Applied Biosystem, USA). Fold expres-
sion was calculated from the triplicate of CT  values
following the 2-ΔΔCt method [24].
RNA Processing
The chemistry involved in the miRNA BeadArray™ was
similar to that used in the DASL amplification process
[21]. Total RNA [200 ng (all 108 samples) and 400 ng (38
technical replicates)] was poly-adenylated and then con-
verted to cDNA using a biotinylated oligo-dT primer with
a universal PCR sequenced at its 5'-end. This was followed
by annealing of a miRNA-specific oligonucleotide pool
(MSO), which consisted of three parts: a universal PCR
priming site at the 5' end; an address sequence comple-
mentary to a capture sequence on the BeadArray™; and a
microRNA-specific sequence at the 3'-end. Extension of
MSO was facilitated by addition of a polymerase but only
if their 3' bases were complementary to the cognate
sequence in the cDNA template. Common primers were
used to amplify the cDNA templates; the primer compli-
mentary to the BeadArray™ was fluorescently labeled. The
single-stranded PCR product was hybridized to the Sentrix
Array Matrix where the labeled strand bound to the bead
on the array containing the complementary address
sequence. The arrays were imaged using an Illumina Bea-
dArray™ Reader, which measures the fluorescence inten-
sity at each addressed bead location. Intensity files were
analyzed using BeadStudio version 3.1.1. Expression lev-
els were expressed as an average Beta value.
Pre-processing and Analyses
Data were exported from Illumina's BeadStudio package,
with neither background correction nor scale correction,
and transformed to the log base 2 scale. Quantile normal-
ization [25] was used as implemented by the R library affy
[26,27]. Samples were distributed on two Illumina SAMs;
systematic effects due to SAM were evaluated and found to
be minimal. A linear mixed-effects model [28] was used
on a probe-by-probe basis to compare expression between
groups accounting for the correlation between replicates
or paired normal-tumor samples from a given subject.
Replicate samples were averaged for further data analyses.
Support Vector Machine Classification (SVM) was carried
out using the Genedata expressionist data analyses suite.
Clustering was carried out on log transformed median
centered data using Cluster 3.0 for Mac OS X (C Clustering
Library 1.43) centroid linkage clustering and was visual-
ized using Java TreeView Version 1.1.3. miRNA tumor
expression data has been submitted to NCBI's Gene
Expression Omnibus (GEO) as ID: GSE18392. Addition-
ally, the data will be searchable on our website http://
www.oncomir.umn.edu.
Genomewide CC methylation data [29], genes implicated
in CC via forward genetic screen [30] and stem cellBMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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miRNA expression data [31] were obtained from publica-
tion. The Diana miRpath application [32] was used to
determine pathway enrichment within the putative targets
for miRNAs found to be altered in CC. miRNA::mRNA
interactions were downloaded from the miRDB version
2.0 database. Custom Perl scripts were used to parse
miRDB, identify predicted miRNA interactions with
tumor suppressor mRNA and identify relationships
between miRNA and methylated regions.
Results
Tissue Specimens
To systematically determine differences in miRNA expres-
sion in colon cancers and their subgroups from normal
colon tissue, the expression levels of 735 miRNA in 108
tissue samples were examined using the Illumina miRNA
detection platform. The characteristics of these tissue sam-
ples are described in Table 1 with additional data pro-
vided [see Additional file 2]. All tumors were
histologically reviewed and macrodissected to ensure that
at minimum 70% of the tumors contained neoplastic cells
to ensure that the majority of tissue extracted was of neo-
plastic origin. The colon tumors were further separated by
mismatch repair status into dMMR (n = 12) of acquired
variety (sporadic) and pMMR groups (n = 68). The
remaining 28 tissue specimens were derived from adja-
cent normal colon tissue removed during tumor resection.
All data, both raw and normalized, is provided [see Addi-
tional file 3].
Technical Array Replicates Show High Level of Correlation
Representative log base 2 intensity plots for direct com-
parison of normalized array data are shown for pairs of
technical replicates, biological replicates and Normal/
Tumor (Figure 1). Technical replicates using either 200 ng
or 400 ng of RNA were used to determine the reproduci-
bility of the Illumina miRNA platform. High Pearson cor-
relation r values were found between technical replicates
even when using different concentrations of RNA for
amplification (Average 0.993; Range {0.977 to 0.997})
(Figure 1A). Lower, but still high, correlations were seen
between biological replicates Normal to Normal (Average
0.984; Range {0.951 to 0.996}) (Figure 1B). The lowest
correlations were seen between normal colon tissue and
tumor tissue [Average 0.967; Range {0.891 to 0.985} (Fig-
ure 1C)].
miRNA Profiles Show Distinct Separation of Tumors from 
Normal Tissue
Unsupervised hierarchical clustering was carried out on
the miRNA expression data (Figure 1D). Analyses of the
dendrogram revealed that normal colon tissue profiles
cluster together in a group separate from the colon tumor
samples (Figure 1D). In addition, normal tissue gave a
tighter internal correlation, signified by higher correla-
tions, than the tumor tissue subset, which as a group
showed less internal correlation.
SVM analyses were used to determine whether the miRNA
profiled by the unsupervised hierarchical clustering are
sufficient to classify the tumor/normal status. SVMs look
for distinctive patterns in groups of data and then use
them to classify group membership status for additional
data. A Monte Carlo cross-validation simulation was set
up to create training sets from 50% of the data and use the
sets to predict tumor/normal status of the remainder of
the dataset with 1000 iterations. Following combination
of the results from all simulations, tumor vs normal status
was correctly classified 100% of the time. The confusion
matrix is included [see Additional file 4].
Differential Expression
A linear mixed effects model was used to determine statis-
tically significant miRNAs differentially expressed in nor-
mal tissue compared with all tumor tissues (Figure 2;
detailed statistics also provided [see Additional file 5]). In
order for a miRNA to be rigorously considered significant,
a p <6.8e-5 was required. This represents the Bonferroni
correction for solving the multiple testing problems asso-
ciated with carrying out 735 individual tests, one for each
miRNA studied on the array. In addition, significantly
altered miRNAs were also required to show a fold change
of absolute value greater than 1.7 to further focus on
miRNA with large expression changes in our high tumor
content samples.
Using these criteria, 39 miRNAs were differentially
expressed between normal colon tissue and the composite
collection of colon tumor tissue (Figure 2A). Many of
these miRNA show similar expression patterns and are
found in close chromosomal proximity. A subset of 17
miRNAs showed increased expression in colon tumors
relative to normal colon tissue. Importantly, miR-135b
displayed the largest average change, a 4.55-fold increase.
miR-96, miR-182, miR-182* and miR-183 were all up-
regulated; expression was highly correlated and mapped
to the same region of chromosome 7. Additionally, 22
miRNAs showed decreased expression in colon tumors.
Table 1: Sample counts of tissues meeting specified 
characteristics analyzed in this study
Characteristic Count
normal colon 28
dMMR/MSIH tumors (sporadic) 12
pMMR Stage II tumor 28
pMMR Stage III tumor 24
pMMR Stage IV tumor 15
pMMR Stage undefined 1
Total Profiled 108BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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Among the down-regulated miRNAs, miR-133a and miR-
1, as well as miR-30a-3p and miR-30a-5p, have a common
chromosomal locus on chromosome 6 and chromosome
18 respectively and also display highly correlated expres-
sion levels. Further, miR-20b and miR-363 show similar
levels and are expressed from a common region on chro-
mosome X.
miRNAs Show Striking Differences with Mismatch Repair 
Status
Direct comparison of dMMR with pMMR tumors by linear
effects mixed model using the Bonferroni correction
revealed that six miRNAs were differentially expressed,
with high significance, between different tumor subtypes
(Figure 2B; detailed statistics provided [see Additional file
5]). miRNAs that showed decreased levels in pMMR rela-
tive to dMMR tumors included miR-552, miR-592, miR-
181c and miR-196b. In contrast, miR-625 and miR-31
exhibited increased levels in dMMR relative to pMMR
tumors.
As expected, unsupervised hierarchical clustering, (Figure
2C) as well as SVM analyses, were able to demonstrate
separation of dMMR from pMMR tumors using statisti-
cally significant miRNAs as defined in Figure 2A-B. How-
ever, separation was not as complete as that observed
between normal and tumor tissues using all probes (Fig-
ure 1D). Examination of the hierarchy generated revealed
that a pMMR tumor subset gave expression patterns
resembling those found in dMMR tumors, when analyz-
ing statistically significant miRNAs. The area for which
SVM was unable to correctly define the tumor MMR status
was also the boundary region observed by unsupervised
hierarchical clustering between dMMR and pMMR
Intensity plots and unsupervised clustering of miRNA profiles Figure 1
Intensity plots and unsupervised clustering of miRNA profiles. (A-C) Log base 2 intensity plots between representa-
tive samples. The equation and Pearson Correlation r values establish the linear fit of data. Comparison of array data obtained 
from (A) a technical replicate - tumor#101 obtained using 200 ng total RNA (x-axis) with the data obtained using 400 ng total 
RNA (y-axis; r = 0.997); (B) a biological replicate - normal#185A (x-axis) with normal#385A (y-axis; r = 0.990); and (C) a nor-
mal tumor comparison - normal#171A (x-axis) with tumor#334 (y-axis; r = 0.918). (D) Unsupervised hierarchical clustering of 
108 miRNA profiles using 735 miRNA.BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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Differentially expressed miRNA between normal colon and tumor tissue Figure 2
Differentially expressed miRNA between normal colon and tumor tissue. Heatmaps of significantly differentially 
expressed miRNAs. All miRNA expression data is shown relative to the average value of normal colon. Both tissue median and 
average fold-change values between the two comparison groups are shown. miRNAs found in close proximity within the 
genome that also show correlation with each other are highlighted in gray. P-values < 10e-16 represented as 0. (A) Normal 
colon samples compared to tumors. (B) dMMR colon cancers are compared to pMMR colon tumors. (C) Unsupervised hierar-
chical clustering of tumors using 43 miRNA found to be significant. Samples improperly defined by SVM cross-validation 
denoted with asterisk.BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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tumors. The SVM confusion matrix for this analysis is
included [see Additional file 4]. Further, unsupervised
clustering was not able to differentiate between pMMR
stages II, III and IV using either the complete dataset or the
statistically significant tumor dataset. Furthermore, no
differences were observed between tumors from males
and females.
dMMR vs pMMR Significant miRNAs Show Differential 
Levels of Response Relative to Normal Colon Tissue
The average fold change of the significantly altered miR-
NAs found in the direct comparison between dMMR
tumors and pMMR tumors was evaluated relative to nor-
mal tissue across all tumor subgroups (Figure 3A). Com-
paring these expression levels with those observed in
normal colon tissue revealed the following patterns: miR-
31 was significantly up-regulated in colon tumors relative
to normal colon tissue and this increase was significantly
greater in dMMR (7-fold) than in pMMR tumors (4-fold).
In addition, miR-552 and miR-592 expression was up-reg-
ulated in pMMR tumors and down-regulated in dMMR
tumors. miR-625 showed increased expression in dMMR
tumors and unchanged in pMMR tumors, relative to nor-
mal tumors. In a directly opposite fashion, miR-196b and
miR-181c show decreased levels of expression only in
dMMR tumors.
Examination of miRNAs showing highly significant
changes in tumor vs normal revealed that the expression
levels for 6 miRNAs were different (p  < 0.05 and fold
change > 1.5) between dMMR and pMMR tumors (Figure
3B). miR-1, miR-133a, miR-328 and miR-9 are further
decreased in dMMR tumors relative to pMMR tumors.
miR-224 was induced slightly in dMMR and further
increased in pMMR tumor. miR-486 was reduced only in
dMMR tumors; and HS-29 was induced to a greater extent
in dMMR tumors than pMMR tumors.
While the majority of miRNAs that were differentially
expressed in pMMR tumors showed similar perturbations
between stages, stage IV pMMR tumors displayed a trend
towards increased levels of a subset of miRNAs, relative to
stage II and stage III pMMR tumors. Six of the miRNAs
identified as highly significant to tumors (HS-29, miR-
135b, miR-32, miR-33, miR-542-5p and miR-96) dis-
played higher expression in pMMR stage IV as compared
to stage II tumors (p < 0.05 and fold change > 1.5) (Figure
3C). The levels found in Stage III tumors trended towards
those identified in Stage II tumors.
Chromosomal Regions Containing Differentially Expressed 
miRNAs Also Show Alterations in DNA Methylation Status
Recently, 2,707 regions of differential DNA methylation
were identified after analyzing ~4.6 million CpG sites in
the human colon cancer genome [29]. Using a window
size of 40,000 bp, statistically significant differentially
expressed miRNAs identified in the current study local-
ized to 28 specific chromosomal regions. Of these, 10 co-
localized to regions differentially methylated in colon
cancer as defined. Using Fisher's Exact test, the null
hypothesis that these events were unrelated was rejected.
Of the 28 regions containing miRNA differentially
expressed in colon cancer, 10 were found in regions in
which a maximum of 2,707 were differentially methyl-
ated in tumors, out of 75,000 potential windows
(3,000,000,000 bases/40,000 base windows). The overlap
between differential miRNA expression and methylation
is much greater than what would be expected by random
chance (p = 2.75e-8) (Table 2A). Of interest, the majority
of these miRNA's (9/10) were repressed in colon tumors.
Additionally, for 8 out of 10 regions, the closest differen-
tially methylated region showed an increase in methyla-
tion (Table 2B).
Validation of miRNA Expression
Array data was validated by by qRT-PCR for 10 miRNAs
(mir-1, miR-10b, miR-135b, miR-147, miR-31, miR-33,
miR-503, miR-552, miR-592, miR-622). This analysis was
performed using RNA from 5 tumor and 2 normal sam-
ples (7 samples total). miRNA expression levels measured
by qRT-PCR showed remarkably similar expression levels
to those obtained by Illumina arrays (Figure 4). Data gen-
erated by these two different methodologies were highly
correlated (Pearson Correlation r = 0.95).
Predicted Targets for miRNAs Significantly Altered in 
Colon Cancer are Enriched in Cancer-related Signaling 
Pathways
The Diana miRpath application [32] was used to define
pathways enriched in the predicted targets for CC signifi-
cant miRNAs. miRpath compiles lists of predicted miRNA
targets and looks for target enrichment in the KEGG path-
way database. The results of the analyses were converted
into a heat map using the -ln(p-value) and were clustered
on the pathway axis and the miRNA putative target axis.
The 174 pathways were filtered down to 27 by addition-
ally requiring the miRNA putative targets to be enriched
((-Ln [p-value]) > 3) in at least 4 of the different pathways.
The results of this analysis is that many pathways describ-
ing specific types of tumors, or signaling pathways involv-
ing oncogenesis show enrichment in the predicted target
lists generated from miRNAs found to be altered in colon
tumors (Figure 5A).
Induced miRNAs are predicted to Target Tumor 
Suppressors
Recently, the results of a forward genetic screen for tumor
suppressors in mice independently validated the role of a
number of genes in intestinal tumorigenesis [30]. There-
fore, we sought to determine whether miRNAs up-regu-BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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Differentially expressed miRNA by tumor subtype Figure 3
Differentially expressed miRNA by tumor subtype. Bar chart describing relative expression levels for each subgroup 
relative to the average expression level in normal tissues. Error bars represent the standard error. (A) miRNA with highly sig-
nificant differences between dMMR and pMMR tumors. (B) Tumor significant miRNA with p < 0.05 and a fold change > 1.5 for 
the comparison of dMMR and pMMR tumors. (C) Tumor significant miRNAs with p < 0.05 and fold change > 1.5 for the com-
parison of pMMR stage II and pMMR stage IV tumors.BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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lated in colon tumors were predicted to interact with the
3' UTR of these tumor suppressors, potentially attenuating
their transcript level/translation status. Of the 15 genes
described as "drivers" of CC [30], interactions were found
between eight genes and 8 miRNAs reported to be up-reg-
ulated in colon tumors in the current study. Furthermore,
in four of these cases, five separate up-regulated miRNAs
were predicted to bind to the 3' UTR of the tumor suppres-
sor (Figure 5B).
Similarities in Colon Cancer and Stem Cell Differentiation
The differentially expressed colon tumor miRNA set was
also looked at in stem cell-related miRNA profiles, previ-
ously published using the Illumina platform (Figure 6A)
[31]. Of interest was the expression profile of the miR-96,
miR-182 and miR-183 clusters as well as miR-135b,
which were up-regulated in embryonic stem cells and
whose expression decreased following differentiation.
Similarly, miR-1, miR-551b, miR-137, miR-30a-3p and
miR-30a-5p were all expressed at lower levels in embry-
onic stem cells relative to differentiated cells. This is con-
sistent with the down-regulation we report for these
miRNAs in colon tumors relative to normal tissue sam-
ples.
Discussion
This study has revealed that a number of miRNAs are
strongly differentially expressed during the development
of CC, including miRNAs not previously reported. Using
the Illumina platform, 39 miRNAs were identified that
show highly statistically significant and meaningful fold
change alterations in CC tumors. The core of this response
showed very similar patterns in all colon tumor types
studied. In addition, six miRNAs were identified that are
significantly differentially expressed in dMMR tumors
compared to pMMR tumors.
Table 2: Fishers Exact test to determine probability of overlap between differentially expressed miRNAs and differentially methylated 
regions in colon cancer and the regions of overlap
A
Regions with Δ miRNA transcript Genomic regions
Regions with Δ methylation 10 2707
Regions with no Δ methylation 18 72293
p-value 2.75e-8
B
Chromosome Location Object Distance (bp) Δ Methylation
X 133131074 miR-363
X 133131505 miR-20b
X 133135052 C-DMR 3547 0.45
X 133507562 C-DMR 462 0.39
X 133508024 miR-503
X 133508504 C-DMR 480 0.42
1 98284214 miR-137
1 98291025 C-DMR 6811 0.37
15 87712252 miR-9*
15 87712252 miR-9
15 87745140 C-DMR 32888 0.39
15 87749926 C-DMR 0.37
16 65755256 C-DMR 38469 0.47
16 65793725 miR-328
2 176711496 C-DMR 11781 0.37
2 176723277 miR-10b
2 219556012 C-DMR 18599 0.53
2 219574611 miR-375
22 21495270 miR-650
22 21526783 C-DMR 31513 -0.56
6 72169975 miR-30a-5p
6 72169975 miR-30a-3p
6 72185916 C-DMR 15941 0.38
6 72187453 C-DMR
8 41637116 miR-486
8 41676418 C-DMR 39302 -0.5
Genomic regions are grouped by alternating bold font. FiguresBMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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As previously described, high-level correlations in the
miRNA data derived from both technical and biological
replicate experiments were observed over a wide range of
detection [21,33]. In addition, the impact of 2-fold fluctu-
ations in the input RNA population was less than the
impact of biological variability between normal samples.
As expected, therefore, distinct expression signatures were
observed in the current study between normal and colon
tumor tissues. Furthermore, unsupervised hierarchical
clustering and SVM results showed that this was robust
and highly predictive in nature.
Several groups have published miRNA profiles of colon
tumors using different platforms with or without an
amplification step: RT-PCR for 150 miRNAs [17], micro-
RNA microarray for 389 miRNAs [18], and LNA-based oli-
gonucleotide arrays for ~315 miRNAs [19]. The present
study is thus the most comprehensive, evaluating 735
miRNAs, the most statistically rigorous, using a Bonfer-
roni correction to the multiple testing problem requiring
large fold changes and used a macrodissected set of tumor
tissues, therefore minimizing the effect from non-malig-
nant cells. Most notably, 18 of the 39 miRNAs we found
significantly altered in CC, have been previously reported
by systematic RT-PCR [17].
Previous work with spotted arrays and qRT-PCR revealed
the induction of miR-21 [17,19] and the repression of
miR-143 [20] in CC compared to normal colon samples.
Surprisingly, these miRNA did not show differential
expression on the Illumina platform. We conducted sepa-
rate qRT-PCR for these miRNAs and were able to see
induction of miR-21 and repression of miR-143 in our
tumor set compared to normal tissue. miR-21 showed a
significant P-value (P = 2.436e-5 but had an average fold
change of only 1.02 between groups. Non-responsive
probes for miR-21 and miR-143 all had very high expres-
sion levels and very low variance, while responsive probes
had higher variance and lower average values.
In order to understand the rationale for this discrepancy,
we plotted the miRNA expression profiles relative to the
average of normal tissue, alongside the absolute raw
expression levels for each probe [see Additional file 6].
Our results demonstrate that miRNAs with high raw
intensity values as well as a negative control, show a tight
distribution of values whereas that distribution is much
more variable in responsive probes. Further comparison
reveals that non-responsive probes have very high expres-
sion levels and very low variance, while responsive probes
have higher variance and lower average values. These
effects are also evident following normalization. Filtering
the expression dataset for probes with high average
expression and low variance reveals 28 probes with these
features [see Additional file 7].
Our observation of high expression "silent" probes is con-
sistent with a probe cDNA hybridization model where all
probe-binding sites are occupied. According to this
model, further increases or decreases in miRNA levels will
not be visible by array analyses due to binding saturation.
This creates a ceiling above which any change, either
increase or decrease in miRNA level, will remain undetec-
table. Additional evidence in support of this model can be
found by looking at the relative concentrations of these
miRNA in deep sequencing. As an example, in some cases
miR-21 made up 50% of the pool in deep sequencing
[21].
Comparison of arrays generated with both the Illumina
platform and spotted arrays for 4 different commonly
used cell lines showed that following removal of high
average expression low variance "silent" Illumina probes,
and low signal probes from the cDNA arrays, the remain-
ing probes cluster together independently of the array
platform [see Additional File 8]. This information coupled
with our qRT-PCR verification of responsive miRNA, indi-
cated that the Illumina arrays have very low false positive
rates; but are potentially susceptible to false negative sig-
nal events.
qRT-PCR validation of miRNA profiling Figure 4
qRT-PCR validation of miRNA profiling. Comparison 
of log base 2 array results to qRT-PCR for 10 miRNAs in 5 
tumors and 2 normals. All qRT-PCR values were normalized 
to U6 snRNA. Error bars indicate the standard error associ-
ated with triplicate qRT-PCR results. Pearson Correlation r 
between the data generated by qRT-PCR and the data gener-
ated by array was 0.95.BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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Functional analyses of miRNAs altered in colon cancer Figure 5
Functional analyses of miRNAs altered in colon cancer. (A) Kegg Pathways enriched in the predicted targets of miR-
NAs perturbed in CC. The results of the analyses were converted into a heatmap using the -ln (p-value). (B) Predicted interac-
tions between miRNAs up-regulated in CC and known CC drivers.BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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dMMR and pMMR tumors showed differential expression
of a small set of miRNA. The molecular etiology of those
tumors involving dMMR is very heterogeneous, involving
several different genes and numerous mechanisms of gene
inactivation, including epigenetic, somatic and germline
alterations. Among sporadic CC, the vast majority of cases
with dMMR are due to inactivation of MLH1  (~95%),
with MSH2 and MSH6 accounting for ~5% and < 1%,
respectively [34]. For MLH1, the most common mecha-
nism (~90% of cases) of gene inactivation is promoter
hypermethylation [35]. In this study, analyses of dMMR
cases were specifically confined to those with loss of
MLH1 due to promoter hypermethylation. This was done
to achieve a homogeneous group. Thus, the results
derived from this study primarily reflect the biology of
sporadic MLH1 CC.
Furthermore, hMLH1 methylation-associated microsatel-
lite instability has also been strongly associated with
tumors that express the CpG Island Methylator Phenotype
(CIMP) [36]. As hMLH1 methylation-associated microsat-
ellite instability generally does not occur among sporadic
cases outside the context of CIMP, it appears that the
underlying basis for mismatch repair deficiency among
this select group of sporadic colon cancer is a broader epi-
genetic control defect that affects hMLH1 in some, but not
all CIMP tumors. CIMP tumors represent another subset
of all CC. Thus, the few pMMR samples that closely resem-
ble the dMMR subset as a group, with respect to the
miRNA profile, may have an underlying CIMP phenotype,
which would be common to both groups. In fact, all but
one of the cases, for which the CIMP phenotype was avail-
able, cluster within a single group containing both dMMR
and pMMR.
Collectively, our data supports a model for colon tumori-
genesis encompassing miRNA::mRNA interactions. In
support of this model, the predicted mRNA target lists
compiled from the 39 altered miRNAs in CC are enriched
in tumorigenesis and cancer-related signaling pathways.
The simplest explanation of this phenomenon is that up-
regulated miRNAs directly or indirectly decrease expres-
sion of tumor suppressor proteins in contrast to down-
regulated miRNAs that may lead to increased oncogene
expression.
The predicted interactions were further explored between
up-regulated miRNAs and a set of "drivers" of CC as
defined by a forward genetic screen in mice [30]. Many of
the induced miRNA found in this study were predicted to
interact with the tumor suppressors. In addition, PTEN
[37], SMAD4 [38], and NOTCH1 [39], are known tumor
suppressors whose transcript or protein levels are
decreased in tumors. miRNA-mediated decreases in
tumor suppressors provide an elegant explanation for the
observed tumor expression patterns.
In this analysis, highly significant increases were observed
in miR-135b in CC and the interaction between miR-135b
and APC was identified as relevant. It has recently been
shown that increased levels of miR-135a/b lead directly to
decreased protein expression of the CC tumor suppressor
APC via a direct binding interaction between miR-135b
and APC mRNA 3' UTR [40]. Although APC mutations are
found in a majority of CC, deregulation of miR-135b may
have an adverse effect on APC in the remainder of cases.
Inadvertent expression and activation of tumor suppres-
sors could easily disrupt normal growth. High levels of
intestinal cell proliferation are required to offset the very
high turnover rate of intestinal tissue [41]. We propose
that miRNA mediated attenuation of transcription/trans-
lation of tumor suppressors is a necessary step in normal
intestinal development allowing for cell proliferation.
With differentiation, the intestinal epithelial cells no
longer replicate, which coincides with a change in miRNA
expression and increased levels of tumor suppressors.
Colon Cancers show partial reactivation of embryonic stem  cell miRNA expression patterns Figure 6
Colon Cancers show partial reactivation of embry-
onic stem cell miRNA expression patterns. (A) Expres-
sion patterns of colon cancer miRNAs showing similar 
changes between differentiated and undifferentiated embry-
onic stem cells. Stem cell miRNA expression data is shown 
relative to the average value of the differentiated stem cells. 
(B) Proposed model for intestinal tumorigenesis.BMC Cancer 2009, 9:401 http://www.biomedcentral.com/1471-2407/9/401
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miRNA expression profiles found in CC show striking
similarities with those miRNA profiles found in undiffer-
entiated embryonic stem cells relative to differentiated
stem cells (Figure 6A) and cancer cell lines [31]. Embry-
onic stem cells and colon tumor cells are both capable of
almost unlimited mitotic division. A potential interpreta-
tion of this observation is that the intestinal crypt cells fail
to properly differentiate and may instead continue to
actively divide leading to tumor formation (Figure 6B).
This is further supported by the observed decreases in
miR-1 and miR-133a, which are involved in maintaining
the differentiation status of muscle cells [42]. In addition,
miR-1 over-expression has been shown to cause expres-
sion of differentiated muscle cell mRNA [43]. The
decreased levels of miR-1 and miR-133a in dMMR tumors
relative to pMMR tumors may also explain why sporadic
CC with dMMR show poor differentiation.
Temporal patterns of gene expression during cell-cell
adhesion-initiated polarization of cultured human Caco-
2 cells found similar transcript changes to those observed
during migration and differentiation of intestinal epithe-
lial cells in vivo, despite the absence of morphogen gradi-
ents and interactions with stromal cells characteristic of
enterocyte differentiation in situ [44]. Here, we propose
that miRNAs may be involved in these changes and that
the miRNA profile within each cell is modified as cells
stop dividing, undergo chromatin remodeling and
become further differentiated with limited ability to repli-
cate.
Taken together, these findings suggest that the inability to
properly differentiate due to loss of epigenetic control
may be an important factor in the development of colon
cancer. The role of induced miRNA found in tumors may
be to (i) drive tumorigenesis by attenuating the transla-
tion of tumor suppressors thereby maintaining a state
capable of cell division; or (ii) act as passengers whose lev-
els reflect that they are locked into a state of uncontrolled
cell replication.
Several basic questions arise from these findings. How
and why are miRNA expression levels altered and how can
they be modified? Our analyses show that miR-135b was
highly up-regulated in colon tumors. PDRM5 is a tumor
suppressor and a target of epigenetic silencing in CC [45].
Of interest, PDRM5 has been shown to bind to the pro-
moter of miR-135b and PDRM5  silencing leads to
increased levels of miR-135b. Mechanistically, PRDM5
recruits HDAC1 and G9a to the miR-135b promoter, and
this chromatin remodeling results in decreased miR-135b
expression. Decreases in PDRM5 expression levels lead to
increased expression of miR-135b presumably due to loss
of recruitment of this chromatin-remodeling complex.
Intriguingly, PDRM5 was also found by CHIP-CHIP to be
present at the promoter regions of miR-9, miR-378, miR-
196b, miR-96-182-183, as well as additional colon cancer
relevant miRNA miR-21 and miR-143-145 [46]. Decreases
in  PDRM5  were associated with both increases and
decreases in miRNA expression. miR-9 was also down-reg-
ulated in invasive breast cancers via promoter hypermeth-
ylation [47]. Therefore, PDRM5-mediated chromatin
remodeling may be a general epigenetic mechanism
related to a wide range of tumors. Drugs that modify chro-
matin structure and methylation status in a sequence spe-
cific fashion may be useful in colon cancer treatment due
to the reversible nature of histone modification and DNA
methylation. Those that modify miRNA transcript level or
mimic/inhibit miRNA function may also be useful.
Conclusion
The data presented here unifies miRNA expression plat-
forms, broadens the miRNAome associated with CC and
defines highly significant differences in miRNA expres-
sion between dMMR and pMMR tumors. We hypothesize
that the differential miRNA expression patterns observed
may modify oncogene and tumor suppressor protein
expression and thereby may promote tumorigenesis by
blocking the proper differentiation of intestinal progeni-
tor cells, consequently leading to improper cell division
and tumor formation. By identifying the miRNA altera-
tions associated with CC at a high level of definition in a
statistically powerful dataset, we have provided an impor-
tant template on which to discover critical biomarkers and
develop more effective treatment protocols for colon can-
cer at all stages.
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